Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Blackburn

Orthopaedic Surgery Folsom, CA Doctor of Osteopathy

NPI 1851687297 CMS profile 1099514

2220 E Bidwell St, Folsom, CA 95630

Open in the dashboard

General payments

$19,111

118 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Blackburn of Folsom, CA is reported in the CMS Open Payments database as having received $19,111 across 118 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,312 7
2024 General $1,908 16
2023 General $5,796 22
2022 General $2,034 12
2021 General $1,256 7
2020 General $2,627 27
2019 General $3,178 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Blackburn
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Brian Blackburn were reported at $2,312. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Brian Blackburn Orthopaedic Surgery median Middle half National median
2019 $3,178 $644 $140–$2,844 $163
2020 $2,627 $312 $75–$1,860 $114
2021 $1,256 $520 $117–$2,495 $132
2022 $2,034 $598 $128–$2,731 $149
2023 $5,796 $461 $128–$2,264 $160
2024 $1,908 $497 $134–$2,475 $164
2025 $2,312 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alphatec Spine, Inc $7,565 22 payments
  2. Medtronic USA, Inc. $2,811 17 payments
  3. Life Spine, Inc. $2,519 8 payments
  4. Medtronic, Inc. $1,936 15 payments
  5. Globus Medical, Inc. $1,397 4 payments
  6. SI-BONE, Inc. $956 14 payments
  7. Stryker Corporation $844 6 payments
  8. Zimmer Biomet Holdings, Inc. $293 11 payments
  9. Clariance, Inc. $118 2 payments
  10. Spineology Inc. $103 1 payment
  11. Other $570 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $14,940 40 payments
  2. Food and Beverage $4,171 78 payments
Products named General payments · program years 2019–2025
  1. Other - Miscellaneous $5,647 14 payments
  2. ProLift Lateral $2,519 8 payments
  3. ProLift Lateral Fixated $2,404 6 payments
  4. AVATAR MINIMALLY INVASIVE SPINAL SYSTEM $2,404 6 payments
  5. Centerline Thoracolumbar Spinal System $2,404 6 payments
  6. Arx $2,404 6 payments
  7. MazorX - Renaissance $2,153 10 payments
  8. STEALTHSTATION S8 PLATFORM $1,248 10 payments
  9. Spine $928 1 payment
  10. NAVIGATOR $692 3 payments
  11. Other $3,845 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

423

Median for Orthopedic Surgery: 203

Drug cost

$6,001

Median for Orthopedic Surgery: $1,433

Branded share of claims

23.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cyclobenzaprine Hcl Generic 111 $2,039
Gabapentin Generic 123 $1,163
Lidocaine Generic 22 $1,093
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 62 $992
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 38 $517
Meloxicam Generic 67 $197

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$248,635

Medicare's payments for the services billed

Medicare patients

387

Average age 71

Services billed

1,724

243 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Diabetes 33%
Depression 27%
Ischemic heart disease 22%
Chronic kidney disease 21%
COPD 21%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record